Augur Signals: News Feed

Category – Medical Instruments & Supplies

Alerts , Healthcare , Medical Instruments & Supplies , RVP

Insider Trading Spotlight: Retractable Technologies, Inc. (RVP)

  • Acquired: Non-Derivative
Insider Trading Spotlight: Retractable Technologies, Inc. (RVP)

Retractable Technologies, Inc. saw a significant insider transaction when Shaw Thomas J, the PRESIDENT AND CEO, bought 3,222 shares at $1.22 each, increasing his direct ownership to 14,176,292 shares. With a history of 42 non-derivative transactions, Shaw's consistent investment behavior aligns with the company's recent short-term stock uptick, despite a negative profit margin. The company holds more cash than debt, with a market capitalization of USD 35,625,268, indicating a potentially bullish outlook from insiders.

Alerts , Healthcare , Medical Instruments & Supplies , STAA

Insider Transaction Spotlight: Broadwood Partners Lp's Latest Acquisition in STAAR Surgical Company

  • Acquired: Non-Derivative
Insider Transaction Spotlight: Broadwood Partners Lp's Latest Acquisition in STAAR Surgical Company
On January 3, 2024, Broadwood Partners Lp purchased 100 shares of STAAR Surgical Company at $28.89 each, totaling $2,920.00. This increased their holdings to 10,764,388 shares. Additionally, they acquired 156,634 shares at $28.48 each, indicating a bullish stance. Despite recent market declines, with a ten-day price change of -9.9%, the insider's activity may suggest confidence in the company's potential. STAAR Surgical Company has a market cap of USD 2,023,415,936 and cash reserves of USD 192,007,008. Other insiders like Frinzi Thomas G have also been trading shares, showing a dynamic insider landscape. Read more...
Alerts , Healthcare , Medical Instruments & Supplies , RVP

Insider Transaction Analysis for Retractable Technologies, Inc.

  • Acquired: Non-Derivative
Insider Transaction Analysis for Retractable Technologies, Inc.

Retractable Technologies, Inc., a leader in the Healthcare sector, saw Thomas J. Shaw, PRESIDENT AND CEO, acquire 4,100 shares at $1.08 each on December 22, 2023. Shaw's stake now totals 14,138,186 shares. Over the past year, Shaw executed 27 transactions, suggesting confidence in the company's future. Despite a 75.5% decline from its peak, the company's market cap stands at USD 35,625,268.00, with substantial cash reserves but negative profitability indicators. Shaw's insider purchases may indicate potential growth and investor opportunity.

Click here to read the full analysis.

Alerts , Healthcare , Medical Instruments & Supplies , ATRI

Insider Transaction Spotlight: Atrion Corporation

  • Acquired: Non-Derivative
Insider Transaction Spotlight: Atrion Corporation

On December 1, 2023, **Preston G. Athey**, a director at **Atrion Corporation**, bought **300 shares** at **$319.68** each, totaling **$94,845.00**. This increased his stake to **1,368 shares**. Athey has a history of acquiring shares, reflecting his long-term confidence in the company. Atrion, a leader in the **Medical Instruments & Supplies** industry, has seen stock volatility, with a market cap of **$610.77 million** and healthy financials, including a gross profit of **$75.90 million**. Athey's recent purchase may indicate a positive outlook for the company's valuation. Discover more about Athey's investment and Atrion's market …

Alerts , Healthcare , Medical Instruments & Supplies , PLSE

Insider Transaction Spotlight: Duggan Robert W's Significant Acquisition in Pulse Biosciences, Inc.

  • Acquired: Non-Derivative
Insider Transaction Spotlight: Duggan Robert W's Significant Acquisition in Pulse Biosciences, Inc.

On November 29, 2023, major shareholder and director Duggan Robert W of Pulse Biosciences, Inc. purchased 158,600 shares at $9.44 per share, totaling approximately $1,465,463.96. This significant investment increases Duggan's ownership to 36,551,461 shares, demonstrating his strong belief in the company's future. Pulse Biosciences has seen a 364.32% stock price increase over the past year, despite a negative free cash flow of -$19,399,876.00. Duggan's consistent share acquisitions highlight a strategic long-term growth vision. For insights into this bullish market move and Pulse Biosciences' potential, [click here to read more](#).

Pages total: 2